---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092779"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:48:06.975369+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alector Q2 net loss $38.7M vs $1.4M income YoY; cash $503M, INVOKE-2 data on track for Q4 2024

## Summary
- Net loss of $38.7M ($0.40 per share) compared to net income of $1.4M in Q2 2023.
- Revenue fell to $15.1M from $56.2M YoY, primarily due to contract modifications on AL101 and AL002 programs.
- Cash, cash equivalents and investments total $503.3M, expected to fund operations through 2026.
- INVOKE-2 Phase 2 data for AL002 in early Alzheimer's disease anticipated in Q4 2024.
- FDA feedback supports potential path to approval for latozinemab in FTD-GRN using biomarkers as confirmatory evidence.

## SEC filing metadata
- accession: 0000950170-24-092779
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017024092779/0000950170-24-092779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017024092779/alec-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092779
- JSON: https://secwatch.observer/filing/0000950170-24-092779.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092779.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.